Selective osteogenesis by a synthetic mineral inducing peptide for the treatment of osteoporosis

Biomaterials

Volumn 35, Issue 37, 2014, Pages 9747-9754

  Park, Yoon Shin ^a   Lee, Jue Yeon ^b   Suh, Jin Sook ^c   Jin, Yoon Mi ^a   Yu, Yeonsil ^a   Kim, Ha Young ^a   Park, Yoon Jeong ^b,c   Chung, Chong Pyoung ^b   Jo, Inho ^a  

^a Ewha Womans University School of Medicine   (South Korea)

^b Nano Intelligent Biomedical Engineering Corporation (NIBEC)   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

Adipogenesis; Collagen binding motif peptide; Osteogenesis; Osteoporosis; Selective differentiation

Indexed keywords

BONE; CELL CULTURE; COLLAGEN; DISEASES; ENZYME ACTIVITY; MAMMALS; STEM CELLS; TISSUE;

ADIPOGENESIS; ADIPOGENIC DIFFERENTIATIONS; BINDING MOTIF; HUMAN MESENCHYMAL STEM CELLS (HMSCS); NON-COLLAGENOUS PROTEINS; OSTEOGENESIS; OSTEOGENIC DIFFERENTIATION; OSTEOPOROSIS;

PEPTIDES;

COLLAGEN BINDING PROTEIN; ESTROGEN; OSTEOCALCIN; OSTEOPONTIN; COLLAGEN; PEPTIDE;

ANIMAL EXPERIMENT; ARTICLE; BONE DENSITY; BONE DEVELOPMENT; BONE MASS; CELL DIFFERENTIATION; CONTROLLED STUDY; ESTROGEN DEFICIENCY; FEMALE; FEMUR HEAD; MESENCHYMAL STEM CELL; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOLYSIS; OSTEOPOROSIS; OVARIECTOMY; PEPTIDE SYNTHESIS; PROTEIN EXPRESSION; 3T3 CELL LINE; ADIPOGENESIS; ANIMAL; BONE; BONE MINERALIZATION; C57BL MOUSE; CELL LINE; CHEMISTRY; DRUG EFFECTS; METABOLISM; PATHOLOGY;

3T3 CELLS; ADIPOGENESIS; ANIMALS; BONE AND BONES; CALCIFICATION, PHYSIOLOGIC; CELL LINE; COLLAGEN; FEMALE; MICE; MICE, INBRED C57BL; OSTEOGENESIS; OSTEOPONTIN; OSTEOPOROSIS; PEPTIDES;

EID: 84907264996     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.08.007     Document Type: Article

References (30)

1. Burge R., Dawson-Hughes B., Solomon D.H., Wong J.B., King A., Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Min Res 2007, 22:465-475.
2. Watts N.B., Harris S.T., Genant H.K., Wasnich R.D., Miller P.D., Jackson R.D., et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990, 323:73-79.
3. Liberman U.A., Weiss S.R., Broll J., Minne H.W., Quan H., Bell N.H., et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The alendronate phase iii osteoporosis treatment study group. N Engl J Med 1995, 333:1437-1443.
4. Cummings S.R., Black D.M., Thompson D.E., Applegate W.B., Barrett-Connor E., Musliner T.A., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures - results from the fracture intervention trial. JAMA J Am Med Assoc 1998, 280:2077-2082.
5. Ahdjoudj S., Fromigue O., Marie P.J. Plasticity and regulation of human bone marrow stromal osteoprogenitor cells: potential implication in the treatment of age-related bone loss. Histology Histopathol 2004, 19:151-157.
6. Gimble J.M., Zvonic S., Floyd Z.E., Kassem M., Nuttall M.E. Playing with bone and fat. J Cell Biochem 2006, 98:251-266.
7. Riggs B.L., Khosla S., Melton L.J. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 2002, 23:279-302.
8. Nuttall M.E., Gimble J.M. Controlling the balance between osteoblastogenesis and adipogenesis and the consequent therapeutic implications. Curr Opin Pharmacol 2004, 4:199-201.
9. Okazaki R., Inoue D., Shibata M., Saika M., Kido S., Ooka H., et al. Estrogen promotes early osteoblast differentiation and inhibits adipocyte differentiation in mouse bone marrow stromal cell lines that express estrogen receptor (ER) alpha or beta. Endocrinology 2002, 143:2349-2356.
10. Muller R., Van Campenhout H., Van Damme B., Van Der Perre G., Dequeker J., Hildebrand T., et al. Morphometric analysis of human bone biopsies: a quantitative structural comparison of histological sections and micro-computed tomography. Bone 1998, 23:59-66.
11. Garnero P., Grimaux M., Demiaux B., Preaudat C., Seguin P., Delmas P.D. Measurement of serum osteocalcin with a human-specific two-site immunoradiometric assay. J Bone Min Res 1992, 7:1389-1398.
12. Suh J.S., Kim K.S., Lee J.Y., Choi Y.J., Chung C.P., Park Y.J. A cell-permeable fusion protein for the mineralization of human dental pulp stem cells. J Dent Res 2012, 91:90-96.
13. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
14. Park Y.S., Huang Y., Park Y.J., David A.E., White L., He H., et al. Specific down regulation of 3T3-L1 adipocyte differentiation by cell-permeable antisense HIF1alpha-oligonucleotide. J Control Rel 2010, 144:82-90.
15. Choi Y.J., Lee J.Y., Lee S.J., Chung C.P., Park Y.J. Determination of osteogenic or adipogenic lineages in muscle-derived stem cells (MDSCs) by a collagen-binding peptide (CBP) derived from bone sialoprotein (BSP). Biochem Biophys Res Commun 2012, 419:326-332.
16. Jun A.Y., Kim H.J., Park K.K., Son K.H., Lee D.H., Woo M.H., et al. Extract of Magnoliae Flos inhibits ovariectomy-induced osteoporosis by blocking osteoclastogenesis and reducing osteoclast-mediated bone resorption. Fitoterapia 2012, 83:1523-1531.
17. Garnero P., Delmas P.D. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab 1993, 77:1046-1053.
18. Harrison's principles of internal medicine Choice Curr Rev Acad Libr 2008, 46:138.
19. Johnell O., Gullberg B., Kanis J.A., Allander E., Elffors L., Dequeker J., et al. Risk factors for hip fracture in European women: the MEDOS Study. Mediterranean Osteoporosis Study. J Bone Min Res 1995, 10:1802-1815.
20. Dempster D.W., Cosman F., Kurland E.S., Zhou H., Nieves J., Woelfert L., et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Min Res 2001, 16:1846-1853.
21. Craik D.J., Fairlie D.P., Liras S., Price D. The future of peptide-based drugs. Chem Biol Drug Des 2013, 81:136-147.
22. Tornvig L., Mosekilde L.I., Justesen J., Falk E., Kassem M. Troglitazone treatment increases bone marrow adipose tissue volume but does not affect trabecular bone volume in mice. Calcif Tissue Int 2001, 69:46-50.
23. Meunier P., Aaron J., Edouard C., Vignon G. Osteoporosis and the replacement of cell populations of the marrow by adipose tissue. A quantitative study of 84 iliac bone biopsies. Clin Orthop Relat Res 1971, 80:147-154.
24. Wang Z., Goh J., Das De S., Ge Z., Ouyang H., Chong J.S., et al. Efficacy of bone marrow-derived stem cells in strengthening osteoporotic bone in a rabbit model. Tissue Eng 2006, 12:1753-1761.
25. Rogers A., Hannon R.A., Eastell R. Biochemical markers as predictors of rates of bone loss after menopause. J Bone Min Res 2000, 15:1398-1404.
26. Delmas P.D., Eastell R., Garnero P., Seibel M.J., Stepan J., Osteoporosis C.S.A.I. The use of biochemical markers of bone turnover in osteoporosis. Osteoporos Int 2000, 11:2-17.
27. Chaki O., Yoshikata I., Kikuchi R., Nakayama M., Uchiyama Y., Hirahara F., et al. The predictive value of biochemical markers of bone turnover for bone mineral density in postmenopausal Japanese women. J Bone Min Res 2000, 15:1537-1544.
28. Nakase T., Takaoka K., Hirakawa K., Hirota S., Takemura T., Onoue H., et al. Alterations in the expression of osteonectin, osteopontin and osteocalcin mRNAs during the development of skeletal tissues in vivo. Bone Min 1994, 26:109-122.
29. Bhattarai T., Bhattacharya K., Chaudhuri P., Sengupta P. Correlation of common biochemical markers for bone turnover, serum calcium, and alkaline phosphatase in post-menopausal women. Malaysian J Med Sci MJMS 2014, 21:58-61.
30. Jiang Y.B., Zhao J.J., Mitlak B.H., Wang O.H., Genant H.K., Eriksen E.F. Recombinant human parathyroid hormone (1-34) [Teriparatide] improves both cortical and cancellous bone structure. J Bone Min Res 2003, 18:1932-1941.